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Juvenile dermatomyositis (JDM) is a rare autoimmune disease mainly characterized by
muscle and skin involvement. Vasculopathy is considered central to the pathogenesis of
the disease. The exact nature of vasculopathy is not yet understood but it is a complex
process with both an inflammatory and a non-inflammatory, occlusive component.
Impaired function of JDM vasculature includes immune complex deposition, altered
expression of cell adhesion molecules predominantly inducing Th17 cell infiltration,
and endothelial cell dysfunction. Development of vasculopathy is associated with the
severe extra-muscular manifestations of JDM, such as gastrointestinal and cardiac
manifestations, interstitial lung disease, ulcerative skin disease or development of
calcinosis, and portends a poor prognosis. Correlation of histopathological findings,
autoantibodies, and extensive diagnostic workup represent key elements to the early
detection of vasculopathic features and early aggressive treatment. Monitoring of
vasculopathy remains challenging due to the lack of non-invasive biomarkers. Current
treatment approaches provide variable benefit, but better understanding of the essential
pathogenic mechanisms should help lead to improved outcomes. Whilst acknowledging
that evidence is limited, this review aims to describe the vasculopathy of JDM in the
context of pathophysiology, clinical features, and treatment of disease.
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INTRODUCTION
Idiopathic Inflammatory Myopathies (IIM) consist of a group of highly heterogenous diseases
characterized by a systemic inflammatory process. Muscle weakness and skin involvement are
common characteristics but other organs can also be affected (1). Juvenile Dermatomyositis (JDM)
is the commonest childhood IIM seen in∼85% of cases, while polymyositis consists of <5% of the
pediatric IIM cases (2). The reported annual incidence of JDM ranges between two to four cases per
one million children per year (2). It is more common in females compared to males, with reported
female: male ratios ranging between 2:1 and 5:1 in different cohorts (2).
The exact etiology of JDM is not fully understood and is thought to be multifactorial. The
prevailing hypothesis is that JDM is the result of genetic susceptibility and environmental triggers,
which subsequently cause dysregulation and dysfunction of the immune system resulting in tissue
inflammation (3). Vasculopathy seems to play a central role in the pathogenesis of myositis and
cutaneous manifestations (4), but is also central to other severe systemic features that contribute
significantly to the burden of disease in children. The vasculopathy associated with JDM is
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thought to underlie the development of intestinal ischaemia and
perforation, cutaneous ulceration, interstitial lung disease, and
calcinosis (5, 6).
The identification of vascular involvement in JDM is
challenging, and depends on extensive immune, histopathologic
and imaging diagnostic approaches together with clinical
experience and expertise. It may influence choice of
therapeutic strategy and prediction of individual patient
prognosis. Therefore, to better understand the pathophysiology,
histopathological findings, clinical manifestations, and associated
complications is of great clinical significance.
PATHOPHYSIOLOGY
The exact nature of vasculopathy remains unclear and is likely
to change at different stages of the disease. Early on there is
evidence of a true inflammatory small vessel vasculitis driven
by interferons and other cytokines (4, 7); but also a later,
non-inflammatory occlusive vasculopathy with capillary drop
out (5, 8). Necrotising capillaritis is seen with complement
deposition in lesional muscle biopsies suggestive of a small vessel
vasculitis mediated by immune complexes (4, 9) (Figures 1A,B).
Immunoglobulin and complement have been identified in the
vessel walls of skeletal muscle in children with JDM (4).
Endothelial cells in the affected muscle produce IL-1 along
with other cytokines (10) and promote inflammation through
paracrine upregulation of endothelial intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-
1 (VCAM-1) (11). Moreover, activated endothelium expresses
binding sites for various chemokines, resulting in attraction
of other inflammatory cells, and has an important effect on
angiogenesis. Angiostatic chemokines are expressed at high levels
in biopsy specimens of untreated JDM patients, correlating with
the degree of capillary loss and mononuclear cell infiltration
(12). Neovascularization may then occur later in the disease
process (13).
Activated dendritic cells present within lesional muscle
release interferons which have a range of biological effects
on the endothelium, such as increased expression of major
histocompatibility complex (MHC) class I and class II and
adhesion molecules promoting T-cell migration (7, 12, 14, 15),
such as macrophage inflammatory protein (MIP), monocyte
chemoattractant protein (MCP)-1, and MCP-2. Involvement of
T cells occurs via lesional T helper type 17 (Th17) cells. The
participation of Th17 cells also seems to lead to induction of IL-
6 and IL-17, which correlate with the interferon response and
with active disease. Indeed, interferons are considered central to
the pathogenesis of JDM and important drivers of the associated
vasculopathy (7).
Later in the course of JDM, the vasculopathy is characterized
by endothelial cell swelling, necrosis, and luminal occlusion
of capillaries and arterioles (5, 8). Another common and well
documented observation in JDM is capillary drop-out, which
is the predominant vasculopathic feature observed in muscle
biopsies and in the skin (8, 16, 17). Occlusive vasculopathy
also contributes significantly to many of the severe late
sequelae of JDM including cutaneous ulceration, intestinal
ischaemia, and ultimately gut infarction (18). It is possible
that occlusive vasculopathy contributes to chronic subcutaneous
calcinosis (19).
The vasculopathy of JDM may present with different clinical
phenotypes. The extent of symptoms includes mild forms limited
to cutaneous vessels, and severe, life-threatening manifestations
with organ involvement. The following section addresses the
pathophysiology and clinical manifestations of disease relating
them where possible to vasculopathy.
Cutaneous Manifestations
JDM is associated with a wide range of skin rashes, illustrated and
described in detail by Dugan et al. (20), but most pathognomonic
is the heliotrope rash involving the upper eye-lids and Gottron’s
papules over the small joints of the hands and large joints
(Figures 2A,B). Periungual erythema and nailfold capillary loop
changes are often present and palmar erythema can be seen (20)
(Figure 2C). Skin ulceration is a serious manifestation of JDM
that can be life threatening. Ulcers presumably mirror significant
vasculopathy in the skin, caused by hypoxia and ischaemia of
the affected tissues and may signal vasculopathy in other organs
(i.e., intestinal ischaemia and perforation, pulmonary fibrosis and
interstitial lung disease) (21, 22). Patients with ulcerative skin
disease are considered to have a more severe disease course with
a worse long-term prognosis (23). Vasculitic ulcers are present
in 23–30% patients (24) and can be seen in particular at the
corner of the eyes (usually heal leaving a chicken-pox-like scar),
and over elbows or other pressure points (5). Periorbital or
generalized edema has been reported in 32% of JDM cases in the
UK cohort (25); usually present at diagnosis or during significant
disease flare. It can relate to a more severe disease course and
indicate resistance to treatment (26). It is considered the result
of a generalized capillary leak due to damage of the vascular
endothelium (26).
Dystrophic calcification of tissues occurs in 20–40% of
patients with JDM, although seen much less frequently in adults
with DM (19). Calcinosis can be complicated by ulceration of
the overlying skin, contractures of the joints when crossing
joint margins (27), pain due to entrapment neuropathy, or
topical inflammation with redness, tenderness, and swelling (24,
28). Nailfold capillary changes seen in JDM include dilatation,
occlusion, bushy loops, hemorrhages, and capillary drop-out
(29), and are present in 80–91% of children at the time of
diagnosis. Nailfold capillaroscopy is a non-invasive technique
that provides quantitative information about the loss of capillary
end-row loops (ERL), areas of decreased or absent vascularity,
and formation of arboreal loops (30). Visualization of the
nailfolds can be easily performed at the bedside with the use of a
light and magnification from a dermatoscope, ophthalmoscope,
or auroscope with or without water soluble gel (24). The
skin around the nail beds can be erythematous (peri-ungual
erythema) and sensitive. Cuticular overgrowth can be seen.
Nailfold changes correlate with prolonged disease course, overall
disease activity, skin disease activity, and poor response to
treatment (30, 31). A similar vessel pattern has been observed
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FIGURE 1 | Muscle biopsy findings in a patient with JDM. (A) Haematoxylin and eosin (H&E) stain showing vessel endothelial swelling. (B) Immunohistochemical
staining for membrane attack complex (MAC) showing deposition on muscle capillaries. Magnification 40x.
FIGURE 2 | Skin changes seen in juvenile dermatomyositis. (A) Heliotrope rash – erythema involving both upper eyelids in a patient with JDM. Written informed parent
consent was obtained for the publication of this image. (B) Gottron’s papules over metacarpal and interphalangeal joints with linear extensor erythema. (C) Palmar
vasculopathy- palmar erythema, most prominent over the joint creases.
in the marginal gingiva that could be part of the vasculopathy
associated with JDM (32).
Cardiac Involvement
Recent case-control echocardiographic studies in children with
JDM have suggested that up to 25% of patients have evidence
of subclinical left ventricular diastolic dysfunction, and a
high prevalence of pathological electrocardiographic (ECG)
abnormalities (33). Children with JDM have also been found to
have reduced heart rate variability which was associated with
impairedmyocardial function suggestive of reduced cardiac vagal
control (34). Whilst studies in children are limited, Rosenbohm
et al. demonstrated signs of subclinical myocardial inflammation
on cardiac MRI scanning in ∼40% of patients with adult onset
inflammatory myositis (35), while pericarditis has also been
reported (36). Hypertension is seen in 25 to 50% patients
probably attributed to both the microvasculopathy of the disease
but also corticosteroid treatment (31). In a recent study of
adults with juvenile onset DM, subclinical cardiovascular disease
and increased carotid intima-media thickness was demonstrated
suggestive of early onset atherosclerosis despite their young age
and absence of other traditional cardiovascular risk factors (37).
Persistence of skin disease activity was shown to correlate with
persistence of cardiac dysfunction in a small follow-up study,
suggesting that a common vasculopathic process affects the
skin and myocardium (30). The significance of this subclinical
cardiac involvement and potential contribution to cardiovascular
morbidity is currently unknown.
Accelerated atherosclerosis has been demonstrated as an
important factor of mortality and morbidity in patients with
autoimmune diseases (38). A recent study comparing patients
with rheumatoid arthritis and patients with diabetes found
equal frequency of atherosclerosis between the two diseases (39).
Regardless of the exact nature of small vessel vasculopathy in
JDM, in the longer term there may be a generalized secondary
systemic vasculopathy affecting larger arteries, ultimately leading
to accelerated atherosclerosis and premature cardiovascular
morbidity later in adulthood. This could be the result of the
primary chronic vasculopathic nature of the disease causing
“polyangiitis overlap,” and/or uncontrolled chronic systemic
inflammation, as in other autoimmune diseases (40). In support
of this, studies of adults with dermatomyositis demonstrate an
almost twice-higher risk of acute myocardial infarction and
stroke when compared to the general population (41, 42).
Interestingly, a small pilot study compared carotid intima-
media thickness (CIMT) and flow-mediated dilatation (FMD) as
surrogate markers of atherosclerosis in 8 adults with a history of
JDM and revealed increased CIMT in JDM patients compared to
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8 healthy controls despite the young age (37). Moreover, recently
a large retrospective study demonstrated that JDMwas associated
with higher odds of cardiovascular and cerebrovascular disease
in adolescents, including atherosclerosis, transient ischaemic
attacks and cerebral infarction (43). It is thus possible that the
combination of chronic endothelial injury caused by persistent
small vessel vasculitis, chronic systemic inflammation, long-
term corticosteroid use, sedentary lifestyle, and conventional
cardiovascular risk factors predispose patients with JDM to early
atherosclerosis.
Gastrointestinal Tract Involvement
Gastrointestinal tract involvement occurs in 5–37% of JDM
cases (24). This includes dysphagia, bowel dysmotility,
vasculitis with associated malabsorption, and other more
severe features of gastro-intestinal vasculopathy that can be
life threatening. Vasculopathy in the gastrointestinal tract
may present with abdominal pain, rectal bleeding, intestinal
ischaemia, pneumatosis, and finally perforation (44). Acute
inflammatory vasculitis and chronic gastrointestinal occlusive
arteriopathy have been described in JDM patients, indicating
that the underlying pathology is complex and multifactorial
(21). Initially inflammatory cells seem to infiltrate the gastric
mucosa and play a significant role in pathogenesis. Persistent
severe abdominal pain is a worrying sign that warrants prompt
investigation and radiographic imaging. The main radiographic
finding is thickening of the bowel mucosal folds demonstrated
by barium swallow and follow-through studies (45).
Pulmonary Vasculitis
Pulmonary involvement is much less common in children with
JDM than adult-onset IIM, but interstitial lung disease (ILD)
may still complicate childhood cases (46). Connective tissue
disease associated-ILD is thought to be initiated bymicrovascular
injury leading to endothelial cell damage and alveolar epithelial
injury (47) leading to the release of numerous cytokines and
growth factors which play a key role in the development of lung
disease. The exact mechanisms are still not fully understood.
Abnormal pulmonary function tests are recorded in more than
half of JDM cases (48). In particular, diffusion capacity may
be decreased at early stages of ILD. Progression can be rapid
and may be life-threatening unless treated aggressively (49).
High serum anti-melanoma differentiation-associated gene 5
(MDA5) antibodies and anti-synthetase antibodies are associated
with rapidly progressive interstitial lung disease. Typically,
ILD presents with increasing cough and progressive dyspnoea,
although it may be asymptomatic. Diffuse alveolar hemorrhage
(DAH) and pneumomediastinum are rare but life-threatening
manifestations of JDM (50–52). Interstitial fibrosis, vasculitis and
infarction have been suggested as possible mechanisms in adults
with DM (53).
Other Organ Involvement
Although rare, vasculopathy of the central nervous system
has been reported in children with JDM (54, 55). It can be
very difficult to diagnose this life-threatening complication. It
most commonly presents with hallucinations and seizures, and
MRI/MRA can be useful diagnostic tools (55). Most reported
cases had active retinal vasculitis (54, 55) suggesting that the
eyes represent another organ that can be affected by JDM
vasculopathy. However, a retrospective review of 82 patients
at a single center demonstrated that retinopathy was rare and
concluded that routine assessment was not warranted for patients
without visual symptoms (56).
MYOSITIS SPECIFIC ANTIBODIES
Myositis specific antibodies (MSA) and myositis associated
antibodies (MAA) are present in at least 60% of JDM cases
(57). Different types of antibodies are associated with specific
clinical manifestations but phenotype may differ according to
the age of the patient at time of disease onset (57). The
commonest MSAs in JDM patients include anti-TIF1γ, anti-
NXP2 and anti-MDA5. Anti-TIF1γ (p155/140) is reported in
23–29% of patients with JDM and is associated with more severe
skin disease, development of skin ulceration and a long disease
course (58), while anti-NXP2 (p140) is mainly connected with
the development of calcinosis in pediatric cases (59). Anti-MDA5
antibodies are associated with mild myositis, arthritis mainly
of the small joints, ulceration of the skin and increased risk of
the disease to be complicated with interstitial lung disease (60).
Recently, a number of anti-endothelial cell antibodies (AECA)
have been identified in the plasma of JDM cases (61), which are
typical of vasculitis and vascular thrombosis in lupus patients
(62). Their clinical and diagnostic significance remains unclear
and needs to be further elucidated. It is not known if specific
antibodies pre-exist the development of the specific disease
features with which they are associated; if so, they could be
useful as prognostic biomarkers and guide further therapeutic
management (57). In support of this, Deakin et al. demonstrated
that MSA in combination with muscle biopsies severity scores
can be predictive of long-term treatment status and prognosis in
children with JDM (63).
TREATMENT
The intensity of initial therapy is determined by the severity
of the presenting symptoms (64) including the presence of
life-threatening weakness, major organ involvement, ulcerative
skin lesions or extensive calcinosis. To date, management
approaches for JDM cases have been mainly based on small
case series and anecdotal experience as only a few randomized
clinical trials exist to guide decisions. In an attempt to
standardize treatment strategies, several therapeutic algorithms
for the treatment of JDM have been published based on expert
consensus inNorth America and Europe (65–69). The Childhood
Arthritis and Rheumatology Research Alliance (CARRA) have
developed Consensus Treatment Plans (CTPs) for the initial
treatment of JDM (69), treatment after the first 3 months
(68), treatment of skin predominant disease (65), and persistent
skin rash (66). It is important to highlight that these CTPs
do not consist of therapeutic guidelines per se, but they
represent arms for proposed comparative effectiveness studies,
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developed via consensus methodologies. Moreover, evidence-
driven consensus-based recommendations for diagnosis and
treatment of JDM have also been published as part of a European
initiative called Single Hub and Access point for pediatric
Rheumatology in Europe (SHARE) (67).
Delayed or inadequate treatment has been associated
with poorer prognosis and early aggressive treatment has
been demonstrated to improve the long-term outcome (70).
Pharmacological interventions for JDM include corticosteroids,
disease-modifying drugs (DMARDs), and biologics agents.
Different steroid regimes have been proposed for the
initial treatment of JDM with the most commonly used
being oral prednisolone or intravenous (IV) pulses with
methylprednisolone. IV methylprednisolone is preferred for
patients with evidence of active vasculopathy as it has been
demonstrated that the absorption of oral prednisolone may be
decreased in children with evidence of loss of nail-fold capillary
ERL by capillaroscopy (71). The exact role of the two different
regimes in the treatment of JDM needs to be further elucidated
(72). Regardless of the regime used, corticosteroid dose is then
tapered over a period of months depending on the response.
Methotrexate (MTX) has become the first line treatment of
JDM, recommended in combination with corticosteroids at
time of diagnosis (66). Ciclosporin has also been used in many
centers as a steroid-sparing agent. In a recent randomized
controlled trial (RCT) where monotherapy with corticosteroids
was compared with the combination of prednisone with either
MTX or ciclosporin, combination therapy had greater efficacy
than corticosteroid alone. More adverse effects were seen
with ciclosporin than MTX, supporting the usual practice of
corticosteroid and MTX as first line treatment (73). Intravenous
immunoglobulin (IVIG) is recommended for patients with JDM
refractory to steroids and methotrexate (67, 68). An alternative
DMARD suggested for severe/refractory cases of JDM or where
methotrexate is not tolerated, is mycophenolate mofetil (67),
beneficial for both muscle and skin disease. MMF has also been
shown to be effective in adult patients with myositis associated
interstitial lung disease (ILD) not responding well to steroid
treatment (74). Azathioprine is less commonly used in JDM (75).
Several therapeutic agents have been proposed for the
treatment of severe/refractory JDM cases. A randomized trial
that included 152 adults with myositis and 48 children with
JDM demonstrated that 83% of patients met the definition of
improvement on rituximab (76), even though the study failed
to reach its primary or secondary endpoints possibly due to
limitations concerning the trial design (77). The overall response
rate, steroid-sparing effect and re-treatment response suggests
that rituximab has a beneficial effect, particularly in children and
those with antibody positive disease (76). In 2008, a case series
reported the efficacy of infliximab in children with refractory
JDM and development of calcinosis (78). Evaluation of 66 JDM
patients, recruited from the UK JDM Cohort and Biomarker
Study and actively treated with anti-TNF agents, both infliximab
and adalimumab showed significant improvements in overall
disease activity, including both muscle and skin involvement
(79). In contrast, etanercept failed to demonstrate efficacy in two
prospective case studies in adult and juvenile dermatomyositis,
respectively (80, 81). There have been reports of TNF inhibitor
induction or exacerbation of DM (82, 83) with the exact
pathophysiological mechanism not yet understood. Abatacept,
a soluble fusion protein comprising the extracellular domain of
human cytotoxic T-lymphocyte associated antigen 4 (CTLA-4)
and a fragment of the Fc domain of human immunoglobulin G1,
has been reported to be effective in a recalcitrant JDM case with
ulcerations and calcinosis (84) and a clinical trial (NCT number:
NCT02594735) is currently underway.
Cyclophosphamide (CyC) is another third line therapeutic
agent mainly reserved for JDM cases refractory to most other
therapies and for cases with significant organ involvement
such as cardiopulmonary involvement, skin ulceration or
gastrointestinal vasculopathy. Several case studies demonstrate
the efficacy of treatment with CyC in both pediatric and adult
patients with IIMs (74, 85). A recent analysis of a UK cohort of
JDM patients treated with CyC indicated good efficacy and low
rates of adverse events (86).
As JDM is now increasingly recognized as a condition
that falls into the category of diseases driven by interferons
(87), JAK inhibition has been suggested as a potential
new targeted therapeutic regime in refractory cases of adult
dermatomyositis (88).
CONCLUSIONS
JDM represents the commonest idiopathic inflammatory
myopathy of childhood. When looking at affected tissues,
vascular and perivascular inflammation is a predominant
feature of the disease, thus early descriptions recognize JDM
as a systemic angiopathy of the childhood. The presence and
persistence of vascular involvement is associated with more
severe and refractory disease and the development of life-
threatening complications. With recent therapeutic strategies,
survival, and outcomes of JDM have improved significantly with
a reported mortality of <2% (89), but the long-term outcome
differs substantially between patients. The exact pathophysiology
of JDM vasculopathy remains unclear and may change over
the course of disease. Complement deposition and endothelial
cells activation with pronounced expression and activation of
adhesive molecules are considered key factors in the pathogenesis
of the disease, while the role of autoantibodies needs to be further
elucidated. Early recognition of vasculopathic features and early
aggressive treatment are key components to a better outcome.
Predicting and monitoring the development of vasculopathy
throughout the disease course remains challenging. Current
therapeutic regimes still lack specificity and in severe cases fail to
control disease activity. Targeting candidate immune pathways
that may be contributing to disease pathogenesis is an active area
of research and an unmet need.
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